Unlocking the language of the heart

Harnessing the power of the electrical signal of the heart to transform cardiac care through cutting-edge AI solutions

divider

Anumana™ is an AI-driven health technology company from nference, building and commercializing AI solutions to improve patient care throughout the cardiac care continuum.

Our Impact

The Impact of AI Algorithms in Cardiology

Listen to Dr. Paul Friedman, a Professor of Medicine and Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Anumana advisor, discuss the potential of AI algorithms in advancing early diagnosis and intervention in cardiology.

Diagnostic Electrocardiography

Diagnostic Electrocardiography

Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate, at times resulting in life-threatening events and creating a multi-billion dollar healthcare burden. Anumana’s AI solutions enable earlier diagnosis of these otherwise hidden diseases, empowering clinicians to intervene with treatments earlier and improve outcomes.

Electrophysiology

Interventional Electrophysiology

Today, the power of AI is just beginning to be leveraged in clinical decision support and has the potential to provide immense value during interventional procedures.​ Anumana’s algorithms and software have the potential to improve procedure accuracy, reduce procedure times, improve medication management, and improve patient safety and outcomes. 

divider

Why Us

Rich, Proprietary Data Fueled R&D

Anumana leverages the largest combined dataset of electrophysiological data, longitudinal patient history, and outcomes in the world. This dataset was developed from multi-year, exclusive data partnerships with leading academic medical centers from Anumana’s parent company, nference. This real-world evidence generation platform, nSights, is inclusive of 11M patients spanning 20+ years and transforms unstructured data (i.e. clinical notes, echocardiogram reports) and semi-structured (i.e. lab tests, medications, appointments, etc) data into labeled data format at scale. This extensive "deep data" platform fuels Anumana's research and development.

Cutting-Edge AI Medical Device Solutions

Anumana transforms research-grade algorithms into medical devices, conducting necessary clinical validation for regulatory clearance, and working with leading clinical experts around the world. Anumana's portfolio includes dozens of first-in-class algorithms, including ECG-AI algorithms for early disease detection and EGM-AI algorithms to improve EP procedures.

Innovative Software and Integrations
Innovative Clinical Software & Integration

Anumana builds and commercializes clinician-facing software and solutions for seamless integration of its technology into existing clinical workflows. Anumana's software solutions integrate with EMRs and other point-of-care technology used within the clinician's existing workflow.

The Tech Tribune
Fierce Biotech
Bostinno
MedCity News
Pulmonary Hypertension News
DAIC
Modern Healthcare
Becker's Hospital Review
Medical Press
Mass Device

Diagnostic Electrocardiography Pipeline

Anumana has a robust FDA-ready pipeline of ECG-AI algorithms, with 75+ peer-reviewed publications that showcase the potential of these algorithms for early cardiovascular disease detection and improved prognosis.

Program
Development
Pre-Submission
Validation
Submission
Market Authorization
Low Ejection Fraction
Novartis

Granted FDA Breakthrough Device Designation

Phase: Validation

Pulmonary Hypertension

Granted FDA Breakthrough Device Designation

Phase: Pre-Submission

Cardiac Amyloidosis

Granted FDA Breakthrough Device Designation

Phase: Pre-Submission

Hyperkalemia

Granted FDA Breakthrough Device Designation

Phase: Pre-Submission

Atrial Fibrillation in Normal Sinus Rhythm

Phase: Pre-Submission

Hypertrophic Cardiomyopathy

Phase: Development

Myocarditis

Phase: Development

Aortic Stenosis

Phase: Development

Early Stage Development Programs

Phase: Development

Electrophysiology Pipeline

Anumana has a highly fertile portfolio of EP applications under development, aiming to increase procedure accuracy, reduce procedure time, and improve patient safety and outcomes.

Program
Development
Pre-Submission
Validation
Submission
Authorization
Hardware Agnostic AI / ML based EAM Software

Phase: Submission

EP Case Review Software

FDA Clearance Not Required

Phase: Validation

Signal Identification Software

Phase: Development

Early Stage Development Programs

Phase: Development

divider

In the Media

Quotes

At Mayo Clinic, AI engineers face an ‘acid test’: Will their algorithms help...

In just the past three years, the team has published more than two dozen studies on AI in cardiology, and it is now field-testing an algorithm to detect a weak heart pump in dozens of primary care clinics.

Stat

Dec. 18th, 2019

Download Our One-Pager

Featuring key corporate highlights and an overview of Anumana's technology